Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cytokinetics (CYTK) Revenue (2016 - 2025)

Cytokinetics (CYTK) has disclosed Revenue for 16 consecutive years, with $86.5 million as the latest value for Q4 2025.

  • Quarterly Revenue changed N/A to $86.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $156.8 million through Dec 2025, changed N/A year-over-year, with the annual reading at $88.0 million for FY2025, 333.52% up from the prior year.
  • Revenue for Q4 2025 was $86.5 million at Cytokinetics, up from $1.9 million in the prior quarter.
  • The five-year high for Revenue was $89.0 million in Q2 2022, with the low at $249000.0 in Q2 2024.
  • Average Revenue over 5 years is $16.6 million, with a median of $2.0 million recorded in 2022.
  • The sharpest move saw Revenue tumbled 99.03% in 2023, then skyrocketed 26714.86% in 2025.
  • Over 5 years, Revenue stood at $40.1 million in 2021, then plummeted by 95.12% to $2.0 million in 2022, then decreased by 14.56% to $1.7 million in 2023, then plummeted by 72.31% to $463000.0 in 2024, then skyrocketed by 18580.78% to $86.5 million in 2025.
  • According to Business Quant data, Revenue over the past three periods came in at $86.5 million, $1.9 million, and $66.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.